<DOC>
	<DOCNO>NCT02690714</DOCNO>
	<brief_summary>This Phase 2/3 pivotal study ProMetic Plasminogen ( Human ) Intravenous Lyophilized solution . The primary objective study achieve consistent increase individual trough plasminogen activity level .</brief_summary>
	<brief_title>A Study ProMetic Plasminogen IV Infusion Subjects With Hypoplasminogenemia</brief_title>
	<detailed_description />
	<mesh_term>Coagulation Protein Disorders</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>Subject male female age 2 80 year ( inclusive ) . Subject documented history lesion symptoms consistent diagnosis hypoplasminogenemia Subject plasminogen activity level â‰¤ 45 % . Subject documented vaccination hepatitis A virus ( HAV ) hepatitis B virus ( HBV ) , receive first dose HAV HBV vaccine prior first dose investigational drug schedule receive second vaccine dose . If subject document vaccination 1 year screen negative antibody titer HAV and/or HBV screening , subject require begin revaccination series first dose HAV and/or HBV vaccine prior first dose investigational drug schedule receive second vaccine dose . No revaccination require documented vaccination take place within 1 year screening . Subject history anaphylactic reaction blood blood product may interfere participation study opinion investigator . Subject uncontrolled hypertension . Subject clinical laboratory evidence intercurrent infection evidence symptom include fever , tachycardia , systemic sign symptom . * Subject pregnant and/or lactating . Subject malignancy , except basal squamous cell skin cancer , within 3 year screen . Subject previous organ transplant recipient . Subject receipt exogenous plasminogen ( ocular IV ) , laboratory grade plasminogen , fresh frozen plasma , Plasminogen ( Human ) within 2 week first dose investigational drug . Subject psychiatric disorder , mental disorder , medical disorder impairs subject 's ability provide inform consent comply requirement study protocol . Subject evidence renal dysfunction define &gt; 2 X upper limit normal ( ULN ) serum creatinine . Subject evidence hepatic dysfunction define &gt; 3 x ULN alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) . Subject participate another institutional review boardapproved interventional clinical trial drug , biologic , device within 30 day first dose investigational drug . Subject chronic acute clinically significant intercurrent illness ( e.g. , cardiac , hepatic , renal , endocrine , neurologic , hematologic , neoplastic , immunological , skeletal ) investigator determines could interfere assessment study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>